Preclinical biotech with deep expertise in functional genomics to map genetic variants and advance a rare disease pipeline led by CB-001.
Constantiam Biosciences has raised $485K in total funding. The most recent round was Grant. The last funding was announced in September 2024.
Constantiam Biosciences's investors include National Institute on Aging, National Human Genome Research Institute.
Constantiam Biosciences is headquartered in Watertown, United States.
Preclinical biotech with deep expertise in functional genomics to map genetic variants and advance a rare disease pipeline led by CB-001.
Constantiam Biosciences is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Constantiam Biosciences — Funding & Investors." VCBacked, September 19, 2024, https://www.vcbacked.co/company/constantiam-biosciences. Accessed September 29, 2026.
VCBacked. (2024). Constantiam Biosciences — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/constantiam-biosciences
{{cite web |title=Constantiam Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/constantiam-biosciences |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated